J&J Faulty Hip Implants: Government Can't Take Action Against J&J Under Existing Laws
The report further recommended that J&J be made liable to pay at least 20 lakh to each affected patient and that the reimbursement programme for revision surgeries continue until August 2025,
New Delhi, August 30: There seems to be no sign of relief for patients fitted with faulty hip implants manufactured by a subsidiary of Johnson & Johnson as there are no specific legal provisions in the existing Drugs and Cosmetics Act, 1940, to provide compensation to the patients in such cases, according to report on Mint. On Tuesday, the Central Drugs Standard Control Organisation (CDSCO) uploaded a report of the faulty hip implants on its website. The report was submitted in February.
The key findings of the committee, as reported by the Indian Express on August 24, constitute the first official indictment in India against J&J, which imported and sold ASR XL Acetabular Hip System and ASR Hip Resurfacing System in the country — these devices were globally recalled in 2010. The panel found that over 3,600 patients with the faulty implants remain untraceable and that at least four patients with the implants have died.
The report further recommended that J&J be made liable to pay at least 20 lakh to each affected patient and that the reimbursement programme for revision surgeries continue until August 2025.
(The above story first appeared on LatestLY on Aug 30, 2018 05:18 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).